- Home
- MPV vs TLSI Comparison
MPV vs TLSI Comparison
Compare MPV & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPV
- TLSI
- Stock Information
- Founded
- MPV 1988
- TLSI 2010
- Country
- MPV United States
- TLSI United States
- Employees
- MPV N/A
- TLSI N/A
- Industry
- MPV Finance Companies
- TLSI Medical Specialities
- Sector
- MPV Finance
- TLSI Health Care
- Exchange
- MPV Nasdaq
- TLSI Nasdaq
- Market Cap
- MPV 181.3M
- TLSI 124.9M
- IPO Year
- MPV N/A
- TLSI N/A
- Fundamental
- Price
- MPV $16.35
- TLSI $4.69
- Analyst Decision
- MPV
- TLSI Strong Buy
- Analyst Count
- MPV 0
- TLSI 6
- Target Price
- MPV N/A
- TLSI $11.75
- AVG Volume (30 Days)
- MPV 25.2K
- TLSI 36.4K
- Earning Date
- MPV 01-01-0001
- TLSI 11-14-2024
- Dividend Yield
- MPV 8.71%
- TLSI N/A
- EPS Growth
- MPV N/A
- TLSI N/A
- EPS
- MPV 1.71
- TLSI N/A
- Revenue
- MPV N/A
- TLSI $26,891,000.00
- Revenue This Year
- MPV N/A
- TLSI $60.96
- Revenue Next Year
- MPV N/A
- TLSI $53.65
- P/E Ratio
- MPV $9.35
- TLSI N/A
- Revenue Growth
- MPV N/A
- TLSI 67.90
- 52 Week Low
- MPV $11.18
- TLSI $3.50
- 52 Week High
- MPV $16.42
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- MPV 31.07
- TLSI 51.68
- Support Level
- MPV $16.51
- TLSI $4.72
- Resistance Level
- MPV $17.38
- TLSI $5.32
- Average True Range (ATR)
- MPV 0.37
- TLSI 0.31
- MACD
- MPV -0.09
- TLSI 0.01
- Stochastic Oscillator
- MPV 2.91
- TLSI 47.52
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.